ALS

Amyotrophic Lateral Sclerosis (ALS)

• ALS is characterized by a progressive decline in motor function due to degeneration of motor neurons.
• Key Differences from Other Diseases:
    - Unlike multiple sclerosis, ALS does not relapse or exacerbate; it progressively worsens.
    - Individuals lose the ability to speak, move, walk, and eventually breathe.

Pathophysiology

• Degeneration occurs in the gray matter of the spinal cord and lower cranial nerves.
• Loss of motor neurons leads to inability to send electrical and chemical messages to muscles.
• Results in:
    - Muscles failing to activate, leading to progressive paralysis.
    - Characteristics of the disease include difficulty speaking, moving, becoming wheelchair-bound, and ultimately death mainly from respiratory failure.

Onset and Demographics

• Most common onset between ages 40-70, affecting males more than females.
• Survival Rates:
    - Death can occur within 3 to 10 years after onset.
    - Progression varies significantly among individuals.
    - Average life expectancy post-diagnosis is often 2-5 years.

Symptoms and Manifestations

• Initial symptoms include:
    - Weakness in voluntary muscles, especially in the extremities.
    - Muscle cramps and spasms.
    - Difficulty swallowing (dysphagia) and choking.
    - Progressive cognitive impairment without affecting intellect.
• Late-stage symptoms include:
    - Complete dependency on caregivers.
    - Inability to eat, speak, or breathe without assistance.
    - Pain due to muscle cramps.

Diagnosis

• No definitive laboratory test exists for ALS.
• Diagnosis usually involves:
    - Electromyography (EMG) to assess muscle electrical activity.
    - Ruling out other conditions such as multiple sclerosis and myasthenia gravis.

Treatment and Management

• Currently no cure for ALS; only symptom management.
• Riluzole and edaravone are medications believed to slow progression in some patients, though not commonly included in nursing exams.
• Importance of advance care planning for end-of-life wishes:
    - Living wills and power of attorney are crucial as the patient deteriorates.
• Frequent care requirements as the disease progresses.

Guillain-Barré Syndrome (GBS)

• GBS is an immune-mediated disease affecting peripheral nerves, possibly following infections.
• Seasonal Changes:
    - Symptoms typically appear 2-4 weeks after preceding infections such as gastroenteritis.

Pathophysiology

• Characteristic changes include:
    - Demyelination and inflammation of nerve roots leading to nerve compression.
• Symptoms start with:
    - Ascending paralysis, typically beginning in the lower extremities and moving upward.
    - Other autonomic symptoms may occur, like bowel and bladder dysfunction.

Symptoms and Progression

• Symptoms can include:
    - Weakness in extremities, numbness, and tingling.
    - Muscle pain, especially at night.
• Sequences of phases:
    - Acute phase (onset of symptoms).
    - Static phase (when symptoms plateau).
    - Rehabilitation phase (gradual recovery).
• Peak symptoms generally at two weeks, may take longer for recovery but significant recovery in most cases is expected.

Diagnosis

• Difficult due to nonspecific symptoms, often mistaken for other conditions (e.g., diabetes).
• Tests used:
    - CSF analysis may show elevated protein levels.
    - Electromyography to assess muscle activity.

Treatment

• Supportive care is the mainstay of treatment, with plasmapheresis for severe cases.
• Recovery rates are generally high, with most patients regaining full function within a year.

Huntington's Disease

• A genetic, progressive neurological disorder marked by chorea and cognitive decline.

Key Characteristics

• Symptoms typically become evident between the fourth and fifth decades of life but can appear earlier.
• Death usually occurs 15-25 years post-diagnosis, primarily due to neurologic degeneration.

Symptoms

• Symptoms include:
    - Chorea (abnormal movements), emotional disturbances, and cognitive decline.
    - Patients have a 50% chance of passing the disorder onto offspring.
    - Neurodegenerative effects lead to loss of coordination and the inability to move independently.

Treatment

• Valbenazine for managing involuntary movements; supportive therapies.

Myasthenia Gravis (MG)

• An autoimmune disease leading to grave muscle weakness affecting voluntary muscles.

Pathophysiology

• Antibodies attack acetylcholine receptors, impairing muscle contraction.
• The disease affects ocular muscles leading to diplopia and ptosis.

Key Symptoms

• Muscle weakness increases with activity and improves with rest.
• Ocular symptoms often precede generalized weakness.

Diagnosis

• Based on clinical presentation, symptom patterns, and confirming the presence of autoantibodies against acetylcholine receptors.

Treatment

• Main treatments include anticholinesterase medications:
    - Neostigmine and pyridostigmine, which prevent acetylcholine breakdown at neuromuscular junctions.
• Plasmapheresis during myasthenic crisis, which can be life-threatening due to respiratory failure.

Management Strategies

• Schedule patient's activities to allow for rest periods optimizing muscle function throughout the day.
• Recognize signs of myasthenic and cholinergic crises, which require immediate medical attention.